Skip to main content
OpenTrials
Completed

NCT Number: NCT05131074

Collabree: A Remote Intervention to Improve the Regularity of Medication Intake

This is a clinical study to improve the regularity of medication intake for high blood pressure. Adult women and men who are over 50 years old, who have received a prescription drug for high blood pressure from MediService, and who have to take at least 4 tablets per day (of which at least 1 dose of medication per day is for high blood pressure) can participate in this study.

The investigators intend to examine whether Collabree, a mobile phone application, is effective in supporting patients with hypertension to more successfully following their therapy plan in order to improve the regularity of medication intake.

The study includes a 90-day intervention phase and a 90-day follow-up. The study does not require any therapy adjustments and no visits to a study center are necessary. The participants conduct the study independently at home. Participants will also fill out questionnaires.

Participants are randomly assigned to one of 3 groups in a ratio of 1: 1: 1. Two of these groups will receive the Collabree mobile phone application.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Behavior Cardiovascular Diseases Health Behavior Medication Adherence Patient Acceptance of Health Care Patient Compliance Treatment Adherence and Compliance Vascular Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Collabree AG

Zurich, Canton of Zurich, 8002, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent as documented by signature.
  • Over 50 years of age on date of randomization.
  • Patient received prescription medicine against hypertension by post from MediService.
  • Prescribed a therapy against hypertension consisting of 4 or more tablets taken per day. At least 1 dose of medication per day must be against hypertension.
  • Participant administers their own medications.
  • Participant owns a smartphone with a data plan or constant internet access during the study reporting events and at home to use the application.
  • Minimal required smartphone operating system is iOS 12 and Android 8 (Oreo).
  • Adequate communication in German or Swiss-German (all study documentation will only be set to the German language).

Exclusion criteria

  • Inability to operate a mobile phone and the Collabree application.
  • Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.
  • Enrollment of the Sponsor-Investigator, their family members, employees, and other dependent persons.
  • Participation in another interventional clinical trial.

Treatment and study plan

Collabree Mobile Phone Application Medication Adherence Booster

Behavioral

Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.

Collabree Mobile Phone Application Medication Adherence Booster (simplified version)

Behavioral

Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.

Primary outcomes

  1. Medication Adherence

    Time frame: 90 days

    Difference between intervention Group A and the control group in mean medication adherence at endpoint (i.e. the endpoint visit at 90 days) as measured by pill count.

Secondary outcomes

  1. Medication adherence (3 group comparison)

    Time frame: 90 days

    Mean change from baseline in medication adherence (monitored by pill count) at endpoint for the intervention Group A vs. intervention Group B relative to the control group.

  2. Self-reported medication adherence

    Time frame: 90 days

    Mean change from baseline in in-app medication adherence (defined as the number of medications self-reported as "taken" during the intervention period of 90 days divided by the number of prescribed medications listed in the in-app medication plan in that same time period) at endpoint for the intervention Group A vs. intervention Group B relative to the control group.

  3. Self-assessed medication adherence

    Time frame: 90 days

    Mean change from baseline in the score on the Hill-Bone Scale (German version) questionnaire on medication adherence for the intervention Group A vs. intervention Group B relative to the control group at endpoint. The Hill-Bone Compliance to Blood Pressure Therapy Scale (German) scores can range from 14 to 56. A higher score means worse compliance.

Sponsors and collaborators

Lead sponsor

Anjali Raja Beharelle

Industry

Collaborators

  • MediService AG

Registry information

Official study title

Collabree: A Targeted Behavioral Economics-based Remote Intervention to Improve Medication Adherence in Patients With Hypertension

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Nov 23, 2021
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.